Leerink, Gilead Sciences
In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Roivant Sciences (ROIV – Research ...
Analysts at Leerink Partnrs lifted their FY2025 EPS estimates for shares of Opthea in a report released on Tuesday, October ...
Leerink Partners analysts are forecasting annual sales of $866 million in 2026, compared to a consensus of $362 million.
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on CYTK stock, giving a Buy rating on October 17. Roanna Ruiz’s ...
Research analysts at Leerink Partnrs cut their Q3 2024 earnings per share (EPS) estimates for Biohaven in a report released ...
On Friday, Aquestive Therapeutics Inc (AQST) stock saw a modest uptick, ending the day at $5.03 which represents a slight increase of $0.11 or 2.24% from the prior close of $4.92. The stock opened at ...
Leerink assumed coverage of Mind Medicine with an Outperform rating and $20 price target The firm likes the emerging ...
Fintel reports that on October 16, 2024, Leerink Partners initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a Outperform recommendation. As of September 25, 2024, the average one ...
Two public companies focused on RNA editing therapies, Korro Bio and ProQR, enjoyed impressive stock surges powered by their best-ever one day gains; their share prices lifted by Wave Life Sciences ...
Leerink Partners has maintained its Market Perform rating and $4.00 price target for Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX). The firm acknowledged the encouraging new HELIOS open-label data for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback